Lupin Will Pay $150M To End Glumetza Antitrust Suit

By Lauren Berg (September 20, 2021, 10:10 PM EDT) -- Direct buyers of blood sugar medication Glumetza on Monday inked a $150 million deal in California federal court with Lupin Pharmaceuticals, which is accused of taking part in a scheme to stave off the launch of a generic version of the blockbuster drug.

Lupin Pharmaceuticals on Monday agreed to pay $150 million to settle claims that it took money from competitors to delay the launch of its generic version of Glumetza. (Dhiraj Singh/Bloomberg via Getty Images) Under the proposed settlement, India-based Lupin Ltd. and its subsidiary Lupin Pharmaceutical Inc. will pay $150 million in cash to resolve claims that the company...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!